<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medical Front Page</title>
	<atom:link href="http://medicalfront-page.com/?feed=rss2" rel="self" type="application/rss+xml" />
	<link>http://medicalfront-page.com</link>
	<description>Medical news you can use from journalists around the world</description>
	<lastBuildDate>Mon, 06 Sep 2010 12:33:34 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Rivaroxaban is Effective and Safe For Treating of Patients With Acute, Symptomatic Deep Vein Thrombosis</title>
		<link>http://medicalfront-page.com/?p=6781</link>
		<comments>http://medicalfront-page.com/?p=6781#comments</comments>
		<pubDate>Mon, 06 Sep 2010 12:33:34 +0000</pubDate>
		<dc:creator>MFP</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://medicalfront-page.com/?p=6781</guid>
		<description><![CDATA[By: Bruce Sylvester
STOCKHOLM, SWEDEN &#8211; Rivaroxaban is effective and safe for treating of patients with acute, symptomatic deep vein thrombosis, researchers said at the European Society of Cardiology Congress 2010.

Results from the phase 3 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism (EINSTEIN-deep vein thrombosis) trial were [...]]]></description>
		<wfw:commentRss>http://medicalfront-page.com/?feed=rss2&amp;p=6781</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Epoetin Alfa Did Not Improve Left Ventricular Ejection Fraction</title>
		<link>http://medicalfront-page.com/?p=6777</link>
		<comments>http://medicalfront-page.com/?p=6777#comments</comments>
		<pubDate>Mon, 06 Sep 2010 12:30:37 +0000</pubDate>
		<dc:creator>MFP</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://medicalfront-page.com/?p=6777</guid>
		<description><![CDATA[By: Bruce Sylvester
STOCKHOLM, SWEDEN &#8211; A single, high-dose treatment with epoetin alfa after a successful percutaneous intervention for ST segment elevation myocardial infarction (STEMI) did not improve left ventricular ejection fraction after 6 weeks, researchers said at the European Society of Cardiology Congress 2010.

Researchers from a prospective, randomised study to examine the effects of a [...]]]></description>
		<wfw:commentRss>http://medicalfront-page.com/?feed=rss2&amp;p=6777</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Atopaxar May Be a Valuable Add-On Therapy For Patients Whose Platelets Remain Activated Despite Current Treatment</title>
		<link>http://medicalfront-page.com/?p=6773</link>
		<comments>http://medicalfront-page.com/?p=6773#comments</comments>
		<pubDate>Mon, 06 Sep 2010 11:30:08 +0000</pubDate>
		<dc:creator>MFP</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://medicalfront-page.com/?p=6773</guid>
		<description><![CDATA[By: Bruce Sylvester
STOCKHOLM, SWEDEN &#8211; Atopaxar (E5555) may be a valuable add-on therapy for patients with acute coronary syndrome or high-risk coronary artery disease whose platelets remain activated despite treatment with current standard therapies, according to researchers presenting at the European Society of Cardiology Congress 2010.

The finding from 2 phase 2 studies (both part of [...]]]></description>
		<wfw:commentRss>http://medicalfront-page.com/?feed=rss2&amp;p=6773</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
